MacroGenics (MGNX)
(Real Time Quote from BATS)
$4.26 USD
-0.02 (-0.35%)
Updated Jul 10, 2024 01:32 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MGNX 4.26 -0.02(-0.35%)
Will MGNX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MGNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MGNX
MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
MGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lantheus Holdings (LNTH) Q4 Earnings and Revenues Beat Estimates
MacroGenics (MGNX) Surges 6.8%: Is This an Indication of Further Gains?
MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why
Other News for MGNX
MacroGenics to Participate in Upcoming Investor Conference
Biotech Alert: Searches spiking for these stocks today
Buy Rating Affirmed for MacroGenics Amidst Promising Oncology Pipeline and Strategic Positioning
MacroGenics (MGNX) Gets a Hold from TD Cowen
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition